Real-World Treatment Patterns In Us Mrcc Patients Who Fail Two Lines Of Targeted Therapy.

e15511 Background: The treatment landscape for mRCC has undergone rapid growth in recent years with the approval of several targeted therapies (TTs). An analysis of real-world treatment patterns in patients who fail two lines of TT using the MarketScan database was recently presented (Pal S et al ASCO GU 2013 [Abstr 231]). The current study aimed to assess treatment patterns in mRCC patients who fail 2nd line TT using the PharMetrics database. Methods: Data were obtained from the PharMetrics database for patients with an RCC diagnosis and at least 3 lines of TT between January 1, 2004 and September 30, 2011. The PharMetrics database covers over 100 health plans across the U.S, and is plan-based, unlike MarketScan which is employer-based. Adult patients with at least 3 months of follow-up prior to initiation of 3rd line TT were included. Treatment patterns were examined for the final sample. Time to treatment discontinuation (TTD) was defined as the time from initiation of 1st line to end of 3rd line TT. P...